Clinical Trial Update: Managing Infliximab Reinduction After Temporary Discontinuation of Drug [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating infliximab reinduction after temporary discontinuation for inflammatory bowel disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: NYU Langone Health | Conditions: Inflammatory Bowel Disease | Phase 3 | Status: WITHDRAWN